Fractyl Health (GUTS) Competitors

$0.91 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.91 0.00 (-0.18%)

As of 05/22/2026 07:59 PM Eastern

GUTS vs. MDXG, NPCE, TCMD, KIDS, and BBNX

Should you buy Fractyl Health stock or one of its competitors? MarketBeat compares Fractyl Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fractyl Health include MiMedx Group (MDXG), NeuroPace (NPCE), Tactile Systems Technology (TCMD), OrthoPediatrics (KIDS), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

How does Fractyl Health compare to MiMedx Group?

Fractyl Health (NASDAQ:GUTS) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Fractyl Health has a beta of 2.11, indicating that its share price is 111% more volatile than the broader market. Comparatively, MiMedx Group has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market.

In the previous week, MiMedx Group had 2 more articles in the media than Fractyl Health. MarketBeat recorded 3 mentions for MiMedx Group and 1 mentions for Fractyl Health. MiMedx Group's average media sentiment score of 0.22 beat Fractyl Health's score of -0.67 indicating that MiMedx Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
MiMedx Group	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

79.2% of MiMedx Group shares are owned by institutional investors. 8.5% of Fractyl Health shares are owned by insiders. Comparatively, 2.5% of MiMedx Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MiMedx Group has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,603.42	-$140.95M	-$1.29	N/A
MiMedx Group	$418.63M	1.29	$48.58M	$0.20	18.10

MiMedx Group has a net margin of 7.88% compared to Fractyl Health's net margin of 0.00%. MiMedx Group's return on equity of 21.03% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-4,053.15%	-96.41%
MiMedx Group	7.88%	21.03%	15.92%

Fractyl Health presently has a consensus target price of $5.40, indicating a potential upside of 493.67%. MiMedx Group has a consensus target price of $8.50, indicating a potential upside of 134.81%. Given Fractyl Health's higher possible upside, equities research analysts plainly believe Fractyl Health is more favorable than MiMedx Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
MiMedx Group	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

MiMedx Group beats Fractyl Health on 12 of the 16 factors compared between the two stocks.

How does Fractyl Health compare to NeuroPace?

NeuroPace (NASDAQ:NPCE) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

78.8% of NeuroPace shares are owned by institutional investors. 20.5% of NeuroPace shares are owned by insiders. Comparatively, 8.5% of Fractyl Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

NeuroPace has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market.

Fractyl Health has a net margin of 0.00% compared to NeuroPace's net margin of -21.67%. NeuroPace's return on equity of -108.20% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
Fractyl Health	N/A	-4,053.15%	-96.41%

In the previous week, NeuroPace had 5 more articles in the media than Fractyl Health. MarketBeat recorded 6 mentions for NeuroPace and 1 mentions for Fractyl Health. NeuroPace's average media sentiment score of 0.51 beat Fractyl Health's score of -0.67 indicating that NeuroPace is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fractyl Health	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

NeuroPace currently has a consensus price target of $18.83, indicating a potential upside of 11.31%. Fractyl Health has a consensus price target of $5.40, indicating a potential upside of 493.67%. Given Fractyl Health's higher probable upside, analysts plainly believe Fractyl Health is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

NeuroPace has higher revenue and earnings than Fractyl Health. NeuroPace is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.77	-$21.47M	-$0.65	N/A
Fractyl Health	$90K	1,603.42	-$140.95M	-$1.29	N/A

Summary

NeuroPace beats Fractyl Health on 12 of the 17 factors compared between the two stocks.

How does Fractyl Health compare to Tactile Systems Technology?

Fractyl Health (NASDAQ:GUTS) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

Fractyl Health has a beta of 2.11, meaning that its share price is 111% more volatile than the broader market. Comparatively, Tactile Systems Technology has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

Tactile Systems Technology has a net margin of 5.91% compared to Fractyl Health's net margin of 0.00%. Tactile Systems Technology's return on equity of 9.70% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-4,053.15%	-96.41%
Tactile Systems Technology	5.91%	9.70%	7.53%

83.4% of Tactile Systems Technology shares are owned by institutional investors. 8.5% of Fractyl Health shares are owned by company insiders. Comparatively, 2.1% of Tactile Systems Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Fractyl Health presently has a consensus target price of $5.40, indicating a potential upside of 493.67%. Tactile Systems Technology has a consensus target price of $38.60, indicating a potential upside of 55.02%. Given Fractyl Health's higher possible upside, equities research analysts plainly believe Fractyl Health is more favorable than Tactile Systems Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86

Tactile Systems Technology has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,603.42	-$140.95M	-$1.29	N/A
Tactile Systems Technology	$329.52M	1.70	$19.09M	$0.88	28.30

In the previous week, Tactile Systems Technology had 5 more articles in the media than Fractyl Health. MarketBeat recorded 6 mentions for Tactile Systems Technology and 1 mentions for Fractyl Health. Tactile Systems Technology's average media sentiment score of 0.39 beat Fractyl Health's score of -0.67 indicating that Tactile Systems Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
Tactile Systems Technology	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Tactile Systems Technology beats Fractyl Health on 13 of the 17 factors compared between the two stocks.

How does Fractyl Health compare to OrthoPediatrics?

Fractyl Health (NASDAQ:GUTS) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

In the previous week, Fractyl Health and Fractyl Health both had 1 articles in the media. OrthoPediatrics' average media sentiment score of 1.17 beat Fractyl Health's score of -0.67 indicating that OrthoPediatrics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative
OrthoPediatrics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

69.1% of OrthoPediatrics shares are held by institutional investors. 8.5% of Fractyl Health shares are held by company insiders. Comparatively, 32.7% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Fractyl Health presently has a consensus price target of $5.40, suggesting a potential upside of 493.67%. OrthoPediatrics has a consensus price target of $24.44, suggesting a potential upside of 33.07%. Given Fractyl Health's higher possible upside, research analysts plainly believe Fractyl Health is more favorable than OrthoPediatrics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Fractyl Health has a beta of 2.11, suggesting that its share price is 111% more volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market.

Fractyl Health has a net margin of 0.00% compared to OrthoPediatrics' net margin of -16.31%. OrthoPediatrics' return on equity of -7.01% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-4,053.15%	-96.41%
OrthoPediatrics	-16.31%	-7.01%	-4.86%

OrthoPediatrics has higher revenue and earnings than Fractyl Health. OrthoPediatrics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,603.42	-$140.95M	-$1.29	N/A
OrthoPediatrics	$236.35M	2.00	-$39.65M	-$1.68	N/A

Summary

OrthoPediatrics beats Fractyl Health on 10 of the 16 factors compared between the two stocks.

How does Fractyl Health compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends, media sentiment and valuation.

Beta Bionics has a beta of 3.29, suggesting that its share price is 229% more volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.11, suggesting that its share price is 111% more volatile than the broader market.

Beta Bionics currently has a consensus target price of $20.00, indicating a potential upside of 69.20%. Fractyl Health has a consensus target price of $5.40, indicating a potential upside of 493.67%. Given Fractyl Health's higher probable upside, analysts clearly believe Fractyl Health is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Beta Bionics has higher revenue and earnings than Fractyl Health. Beta Bionics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	5.25	-$73.20M	-$1.51	N/A
Fractyl Health	$90K	1,603.42	-$140.95M	-$1.29	N/A

Fractyl Health has a net margin of 0.00% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Fractyl Health	N/A	-4,053.15%	-96.41%

In the previous week, Beta Bionics had 3 more articles in the media than Fractyl Health. MarketBeat recorded 4 mentions for Beta Bionics and 1 mentions for Fractyl Health. Beta Bionics' average media sentiment score of -0.22 beat Fractyl Health's score of -0.67 indicating that Beta Bionics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fractyl Health	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Negative

Summary

Beta Bionics beats Fractyl Health on 10 of the 15 factors compared between the two stocks.

Get Fractyl Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GUTS vs. The Competition

Export

Metric	Fractyl Health	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$144.31M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-0.71	17.79	21.21	25.65
Price / Sales	1,603.42	336.21	554.38	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	7.00	5.86	10.37	7.14
Net Income	-$140.95M	$74.99M	$3.57B	$335.98M
7 Day Performance	11.32%	3.11%	6.40%	4.15%
1 Month Performance	46.71%	-3.05%	3.53%	2.54%
1 Year Performance	-49.47%	34.38%	34.04%	35.06%

Fractyl Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GUTS Fractyl Health	3.0855 of 5 stars	$0.91 flat	$5.40 +493.7%	-49.5%	$144.31M	$90K	N/A	102	Gap Up
MDXG MiMedx Group	3.5419 of 5 stars	$3.59 +0.8%	$8.50 +136.8%	-45.4%	$530.25M	$418.63M	17.95	870
NPCE NeuroPace	2.9388 of 5 stars	$15.99 +4.1%	$18.83 +17.8%	-4.3%	$523.68M	$99.99M	N/A	170
TCMD Tactile Systems Technology	4.0117 of 5 stars	$23.65 +4.0%	$38.60 +63.2%	+164.3%	$512.93M	$329.52M	26.88	1,086
KIDS OrthoPediatrics	3.6759 of 5 stars	$18.14 +2.4%	$24.44 +34.8%	-11.8%	$455.14M	$236.35M	N/A	200	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GUTS) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fractyl Health (GUTS) Competitors

GUTS vs. MDXG, NPCE, TCMD, KIDS, and BBNX

How does Fractyl Health compare to MiMedx Group?

Summary

How does Fractyl Health compare to NeuroPace?

Summary

How does Fractyl Health compare to Tactile Systems Technology?

Summary

How does Fractyl Health compare to OrthoPediatrics?

Summary

How does Fractyl Health compare to Beta Bionics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fractyl Health (GUTS) Competitors

GUTS vs. MDXG, NPCE, TCMD, KIDS, and BBNX

How does Fractyl Health compare to MiMedx Group?

Which has more volatility and risk, GUTS or MDXG?

Does the media refer more to GUTS or MDXG?

Do institutionals and insiders believe in GUTS or MDXG?

Which has higher earnings & valuation, GUTS or MDXG?

Is GUTS or MDXG more profitable?

Do analysts recommend GUTS or MDXG?

Summary

How does Fractyl Health compare to NeuroPace?

Do insiders and institutionals have more ownership in NPCE or GUTS?

Which has more risk & volatility, NPCE or GUTS?

Is NPCE or GUTS more profitable?

Does the media prefer NPCE or GUTS?

Do analysts recommend NPCE or GUTS?

Which has better earnings and valuation, NPCE or GUTS?

Summary

How does Fractyl Health compare to Tactile Systems Technology?

Which has more risk and volatility, GUTS or TCMD?

Is GUTS or TCMD more profitable?

Do insiders & institutionals have more ownership in GUTS or TCMD?

Do analysts prefer GUTS or TCMD?

Which has higher valuation and earnings, GUTS or TCMD?

Does the media favor GUTS or TCMD?

Summary

How does Fractyl Health compare to OrthoPediatrics?

Does the media refer more to GUTS or KIDS?

Do institutionals and insiders have more ownership in GUTS or KIDS?

Do analysts rate GUTS or KIDS?

Which has more volatility & risk, GUTS or KIDS?

Is GUTS or KIDS more profitable?

Which has stronger valuation and earnings, GUTS or KIDS?

Summary

How does Fractyl Health compare to Beta Bionics?

Which has more volatility & risk, BBNX or GUTS?

Do analysts prefer BBNX or GUTS?

Which has higher valuation & earnings, BBNX or GUTS?

Is BBNX or GUTS more profitable?

Does the media prefer BBNX or GUTS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools